Skip to main content

Table 1 Baseline characteristics

From: Isoflurane, like sepsis, decreases CYP1A2 liver enzyme activity in intensive care patients: a clinical study and network model

Parameter

All patients

(n = 22)

With sepsis

(n = 11)

Non-septic (n = 11)

p-value

sepsis vs

non-septic

Age (yr)

58 [49, 71]

56 [30, 73]

59 [51, 80]

0.3

Sex (n)

    

Female

8

5

6

 

Male

14

6

5

 

Weight (kg)

90 [75, 99]

90 [60, 105]

90 [75, 95]

0.47

Height (cm)

179 [169, 180]

173 [166,180]

180 [178, 185]

0.29

BMI (kg/m2)

28 [25, 31]

30 [22, 31]

27 [26, 29]

0.68

SOFA score

10 [9, 12]

11 [10, 13]

9 [8, 10]

0.01

APACHE II score

22 [19, 26]

26 [18, 33]

21 [19, 24]

0.15

28-day mortality (n)

3 (14%)

1 (9%)

2 (18%)

0.56

Duration of propofol sedation before isoflurane (h)

51 [20, 87]

51 [46, 72]

48 [20, 88]

0.53

Duration of isoflurane sedation (h)

151 [71, 238]

164 [128, 243]

85 [50, 234]

0.17

Time interval T0–T3 (h)

263 [167, 459]

336 [179, 515]

242 [163, 379]

0.17

Time interval T0–T1 (h)

42 [24, 69]

56 [26, 97]

30 [24, 46]

0.116

Time interval T1–T2 (h)

43 [24, 96]

74 [25, 127]

25 [24, 70]

0.156

Time interval T2–T3 (h)

158 [104, 292]

147 [105, 359]

189 [95, 243]

0.758

Patients on drugs with CYP1A2

   

n/a

 Inhibition (n)

7

3

4

 

 Induction (without PPI’s)(n)

10

6

4

 

Admission diagnosis

   

n/a

 Trauma

4

1

3

 

 Gastrointestinal disease

7

5

3

 

 Pulmonary disease

7

5

1

 

 Neurologic disorder

4

0

4

 

Comorbidities (n)

   

n/a

 Cardiovascular

12

7

5

 

 Pulmonary

6

5

1

 

 Diabetes

6

3

3

 

 Neurological

4

2

2

 

 BMI ≥ 35

1

0

1

 
  1. Parameters are reported as median [IQR]. Medication given at any time point: CYP1A2 inhibitors: fluoroquinolones. CYP1A2 inductors: insulin. All patients had received PPI’s (proton pump inhibitors). SOFA and APACHE II score were evaluated at T0. BMI: body mass index, SOFA: Sepsis-Related Organ Failure Assessment, APACHE II: Acute Physiology and Chronic Health Evaluation, CYP1A2: cytochrome P450 1A2